The role of annexin II in angiogenesis and tumor progression: A potential therapeutic target

Current Pharmaceutical Design

Volumn 13, Issue 35, 2007, Pages 3568-3575

  Sharma, Mahesh C ^a   Sharma, Meena ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Angiogenesis; Angiostatin; Annexin II; Cancer; Plasmin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; LIPOCORTIN 2; MONOCLONAL ANTIBODY; PLASMIN; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

ANTIANGIOGENIC ACTIVITY; BASEMENT MEMBRANE; BINDING AFFINITY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EVIDENCE BASED MEDICINE; EXPERIMENTAL NEOPLASM; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TISSUE SPECIFICITY; TUMOR CELL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANNEXIN A2; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; PLASMINOGEN; PROGNOSIS; RECEPTORS, CELL SURFACE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 36949012954     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782794167     Document Type: Review

References (81)

1. Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost 2001; 86: 346-55.
2. Tarui T, Majumdar M, Miles LA, Ruf W, Takada Y. Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J Biol Chem 2002; 277: 33564-70.
3. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-95.
4. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-33.
5. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001; 21: 1104-17.
6. Stack MS, Gately S, Bafetti LM, Enghild JJ, Soff GA. Angiostatin, inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77-84.
7. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM, et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103: 317-24.
8. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998; 13: 893-906.
9. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-74.
10. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15: 105-11.
11. Costantini V, Zacharski LR, Memoli VA, Kudryk BJ, Rousseau SM, Stump DC. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Cancer Res 1991; 51: 354-8.
12. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-84.
13. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003; 60: 463-73.
14. Stephens RW, Brunner N, Janicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99-111.
15. Rabbani SA, Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002; 62: 2390-7.
16. Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures. Clin Chem Lab Med 2000; 38: 679-92.
17. Hajjar KA, Krishnan S. Annexin II: a mediator of the plasmin/plasminogen activator system. Trends Cardiovasc Med 1999; 9: 128-38.
18. Kang HM, Choi KS, Kassam G, Fitzpatrick SL, Kwon M, Waisman DM. Role of annexin II tetramer in plasminogen activation. Trends Cardiovasc Med 1999; 9: 92-102.
19. Glenney JR, Jr. Calpactins: calcium-regulated membrane-skeletal proteins. Biochem Soc Trans 1987; 15: 798-800.
20. Swairjo MA, Seaton BA. Annexin structure and membrane interactions: a molecular perspective. Annu Rev Biophys Biomol Struct 1994; 23: 193-213.
21. Boyko V, Mudrak O, Svetlova M, Negishi Y, Ariga H, Tomilin N. A major cellular substrate for protein kinases, annexin II, is a DNA-binding protein. FEBS Lett 1994; 345: 139-42.
22. Dubois T, Oudinet JP, Russo-Marie F, Rothhut B. In vivo and in vitro phosphorylation of annexin II in T cells: potential regulation by annexin V. Biochem J 1995; 310: 243-8.
23. Keutzer JC, Hirschhorn RR. The growth-regulated gene 1B6 is identified as the heavy chain of calpactin I. Exp Cell Res 1990; 188: 153-9.
24. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, et al. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 2001; 98: 9824-9.
25. Hajjar KA, Guevara CA, Lev E, Dowling K, Chacko J. Interaction of the fibrinolytic receptor, annexin II, with the endothelial cell surface. Essential role of endonexin repeat 2. J Biol Chem 1996; 271: 21652-9.
26. Masaki T, Tokuda M, Fujimura T, Ohnishi M, Tai Y, Miyamoto K, et al. Involvement of annexin I and annexin II in hepatocyte proliferation: can annexins I and II be markers for proliferative hepatocytes? Hepatology 1994; 20: 425-35.
27. Sharma M, Rothman VL, Tuszynski GPa, Sharma MC. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: Possible biochemical mechanism of angiostatin's action. Exp Mol Pathol 2006; 81: 136-45.
28. Sharma M, Koltowski L, Rothman VL, Tuszynski GP, and RTO, Sharma MC. Angiogenesis Associated Protein Annexin II in Breast Cancer: Selective Expression in Invasive Breast Cancer and Contribution to Tumor Invasion and Progression. Exp Mol Pathol 2006; 81: 146-56.
29. Zimmermann U, Woenckhaus C, Pietschmann S, Junker H, Maile S, Schultz K, et al. Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome. Virchows Arch 2004; 445: 368-74.
30. Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis 2002; 19: 319-26.
31. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-203.
32. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994-1004.
33. Falcone DJ, Borth W, Khan KM, Hajjar KA. Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II. Blood 2001; 97: 777-84.
34. Diaz VM, Hurtado M, Thomson TM, Reventos J, Paciucci R. Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro. Gut 2004; 53: 993-1000.
35. Reeves SA, Chavez-Kappel C, Davis R, Rosenblum M, Israel MA. Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res 1992; 52: 6871-6.
36. Roseman BJ, Bollen A, Hsu J, Lamborn K, Israel MA. Annexin II marks astrocytic brain tumors of high histologic grade. Oncol Res 1994; 6: 561-7.
37. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 2002; 63: 159-71.
38. Hajar KA, Harpel PC, Jaffe EA, Nachman RL. Binding of plasminogen to cultured human endothelial cells. J Biol Chem 1986; 261: 11656-62.
39. Hajjar KA, Menell JS. Annexin II: a novel mediator of cell surface plasmin generation. Ann N Y Acad Sci 1997; 811: 337-49.
40. Chung CY, Erickson HP. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J Cell Biol 1994; 126: 539-48.
41. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7: 883-92.
42. Mignatti P, Rifkin DB. Plasminogen activators and angiogenesis. Curr Top Microbiol Immunol 1996; 213: 33-50.
43. Diaz VM, Planaguma J, Thomson TM, Reventos J, Paciucci R. Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells. Gastroenterology 2002; 122: 806-19.
44. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
45. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998; 12: 1731-8.
46. Claesson-Welsh L, Welsh M, Ito N, Anand-Apte B, Soker S, Zetter B, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci USA 1998; 95: 5579-83.
47. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998; 92: 4730-41.
48. Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57: 1329-34.
49. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284(5415): 808-12.
50. Tuszynski GP, Sharma M, Rothman VL, Sharma MC. Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells. Microvasc Res 2002; 64: 448-62.
51. Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J Clin Invest 2004; 113: 38-48.
52. Semov A, Moreno MJ, Onichtchenko A, Abulrob A, Ball M, Ekiel I, et al. Metastasis-associated protein S100A4 induces angiogenesis through interaction with Annexin II and accelerated plasmin formation. J Biol Chem 2005; 280: 20833-41.
53. Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet 1989; 2: 1049.
54. Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
55. Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
56. Collen D, Lijnen HR. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995; 74: 167-71.
57. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
58. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997; 425: 89-97.
59. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49: 636-49.
60. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-44.
61. McColl BK, Baldwin ME, Roufail S, Freeman C, Moritz RL, Simpson RJ, et al. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 2003; 198: 863-8.
62. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000; 12: 613-20.
63. O'Reilly MS, Holingren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-92.
64. Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003; 278: 45826-32.
65. Aguilar S, Corominas JM, Malats N, Pereira JA, Dufresne M, Real FX, et al. Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression. Am J Pathol 2004; 165: 1129-39.
66. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res 2001; 21: 1339-45.
67. Liu JW, Shen JJ, Tanzillo-Swarts A, Bhatia B, Maldonado CM, Person MD, et al. Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene 2003; 22: 1475-85.
68. Banerjee AG, Liu J, Yuan Y, Gopalakrishnan VK, Johansson SL, Dinda AK, et al. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol Cancer 2003; 2: 34.
69. Drixler TA, Vogten MJ, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE, et al. Liver regeneration is an angiogenesis-associated phenomenon. Ann Surg 2002; 236(6): 703-11.
70. Drixler TA, Vogten JM, Gebbink AV, Carmeliet P, Voest EE, Borel Rinkes IH. Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomy. Br J Surg 2003; 901: 1384-90.
71. Frohlich M, Motte P, Galvin K, Takahashi H, Wands J, Ozturk M. Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma. Mol Cell Biol 1990; 10: 3216-23.
72. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 269: 21191-7.
73. Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 1997; 236: 651-4.
74. Bugge TH, Kombrinck KW, Xiao Q, Holmback K, Daugherty CC, Witte DP, et al. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997; 90: 4522-31.
75. Kimura Y, Baba K, Okuda H. Inhibitory effects of active substances isolated from Cassia garrettiana heartwood on tumor growth and lung metastasis in Lewis lung carcinoma-bearing mice (Part 1). Anticancer Res 2000; 20: 2899-906.
76. Kobayashi H, Shinohara H, Fujie M, Gotoh J, Itoh M, Takeuchi K, et al. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Int J Cancer 1995; 63: 455-62.
77. Tanaka N, Ogawa H, Kinjo M, Kohga S, Tanaka K. Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma. Br J Cancer 1982; 46: 428-35.
78. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998; 101: 1055-63.
79. Carragher NO. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006; 12(5): 615-38.
80. Matsuno H. Alpha2-antiplasmin on cardiovascular diseases. Curr Pharm Des 2006;. 12(7): 841-7.
81. Ueshima S, Matsuo O, Development of new fibrinolytic agents. Curr Pharm. Des 2006; 12(7): 849-57.